Alain Matagne

The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam

Berkley A. Lynch, Nathalie Lambeng, Karl Nocka et al. · Proceedings of the National Academy of Sciences · 2004 · 1.6K citations · Full text

New Antiepileptic Drug, Molecular Neuroscience, Antiepileptic Drug Levetiracetam +15

The anti‐epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA‐ and glycine‐gated currents

Jean‐Michel Rigo, Grégory Hans, Laurent Nguyen et al. · British Journal of Pharmacology · 2002 · 332 citations · Full text

The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes

Michel Noyer, Michel Gillard, Alain Matagne et al. · European Journal of Pharmacology · 1995 · 253 citations

Medicine, Cns Membranes, Neuropharmacology +8

Discovery of 4-Substituted Pyrrolidone Butanamides as New Agents with Significant Antiepileptic Activity

Benoît Kenda, Alain Matagne, Patrice Talaga et al. · Journal of Medicinal Chemistry · 2003 · 222 citations · Full text

New Agents, Drug Target, Pharmaceutical Science +18

Anti‐convulsive and anti‐epileptic properties of brivaracetam (ucb 34714), a high‐affinity ligand for the synaptic vesicle protein, SV2A

Alain Matagne, D‐G Margineanu, Benoît Kenda et al. · British Journal of Pharmacology · 2008 · 219 citations · Full text